Phosphotidylinositol 3-kinase inhibitors

US10947225B2 · kind B2 · utility

Assignee

• EMORY UNIVERSITY · US

Inventors

• Qi Shi · Edison, US
• Thomas Kaiser · Hohlstedt, DE
• John DiRaddo · Fairport, US
• James P. Snyder · Atlanta, US
• Dennis C. Liotta · Atlanta, US
• Zackery Dentmon · East Point, US

Key dates

• Filing date: May 11, 2017
• Grant date: Mar 16, 2021
• Expiry date: May 11, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure relates to phosphoinositide 3-kinases (PI3Ks) inhibitors such as N-(5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)sulfonamide derivatives and uses related thereto. In certain embodiments, the disclosure relates to methods of treating PI3K associated diseases or conditions comprising administering an effective amount of a compound disclosed herein to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, suffering from, or diagnosed with cancer or a hematological malignancy.